WO2004067774A2 - Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament - Google Patents
Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament Download PDFInfo
- Publication number
- WO2004067774A2 WO2004067774A2 PCT/EP2004/000539 EP2004000539W WO2004067774A2 WO 2004067774 A2 WO2004067774 A2 WO 2004067774A2 EP 2004000539 W EP2004000539 W EP 2004000539W WO 2004067774 A2 WO2004067774 A2 WO 2004067774A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- polypeptide
- polymoφhic
- drug
- genes
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure such as high-output and low-output, acute and chronic, right- sided or left-sided, systolic or diastolic, independent of the underlying cause.
- MI Myocardial infarction
- the first observable event in the formation of an atherosclerotic plaque occurs when blood-borne monocytes adhere to the vascular endothelial layer and transmigrate through to the sub-endothelial space. Adjacent endothelial cells at the same time produce oxidized low density lipoprotein (LDL). These oxidized LDLs are then taken up in large amounts by the monocytes through scavenger receptors expressed on their surfaces. In contrast to the regulated pathway by which native LDL (nLDL) is taken up by nLDL specific receptors, the scavenger pathway of uptake is not regulated by the monocytes.
- LDL low density lipoprotein
- the invention may also be of use in confirming or corroborating the results of other diagnostic methods.
- the diagnosis of the invention may thus suitably be used either as an isolated technique or in combination with other methods and apparatus for diagnosis, in which latter case the invention provides a further test on which a diagnosis may be assessed.
- Atherosclerosis Complications of atherosclerosis are the most common causes of death in Western societies.
- atherosclerosis can be considered to be a form of chronic inflammation resulting from interaction modified lipoproteins, monocyte-derived macrophageSjT cells, and the normal cellular elements of the arterial wall. This inflammatory process can ultimately lead to the development of complex lesions, or plaques, that protrude into the arterial lumen. Finally plaque rupture and thrombosis result in the acute clinical complications of myocardial infarction and stroke (Glass et al., Cell 2001, 104:503-516).
- alleles refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for the gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from each other in a single nucleotide, or several nucleotides, and can include substitutions, deletions, and insertions of nucleotides.
- An allele of a gene can also be a form of a gene containing a mutation.
- allelic variant of a polymorphic region of a gene refers to a region of a gene having one of several nucleotide sequences found in that region of the gene in other individuals.
- polymorphism refers to the coexistence of more than one form of a gene or portion thereof.
- a portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a "polymorphic region of a gene".
- a polymorphic region can be a single nucleotide, the identity of which differs in different alleles.
- a polymorphic region can also be several nucleotides long.
- transcription factors are active only if they are phosphorylated on specific residues.
- transcription factors can be active in the absence of phosphorylated residues and become inactivated by phosphorylation.
- a list of known transcription factors and their DNA binding site can be found, e.g., in public databases, e.g., TFMATRIX Transcription Factor Binding Site Profile database.
- Interventions with pharmaceutical agents not yet known whose activity correlates with particular polymo ⁇ hic patterns associated with cardiovascular disease are also encompassed. It is contemplated, for example, that patients who are candidates for a particular therapeutic regimen will be screened for polymo ⁇ hic patterns that correlate with responsivity to that particular regimen.
- allelic variant of the nucleotide polymo ⁇ hism of nucleotide A or G at position 33 of Seq ID 1 (baySNP179) and that of other possible polymo ⁇ hic regions can be determined in a single hybridization experiment.
- the whole PCR reaction is transferred into a PSQ plate TM (Pyrosequencing) and prepared using the Sample Prep Tool TM and SNP Reagent Kit TM from Pyrosequencing according to their instructions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04704556A EP1592808A2 (fr) | 2003-01-31 | 2004-01-23 | Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03002212.3 | 2003-01-31 | ||
EP03002212 | 2003-01-31 | ||
EP03002153.9 | 2003-02-03 | ||
EP03002153 | 2003-02-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004067774A2 true WO2004067774A2 (fr) | 2004-08-12 |
WO2004067774A3 WO2004067774A3 (fr) | 2004-10-21 |
Family
ID=32826771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/000539 WO2004067774A2 (fr) | 2003-01-31 | 2004-01-23 | Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1592808A2 (fr) |
WO (1) | WO2004067774A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071382A2 (fr) * | 2005-12-22 | 2007-06-28 | Siemens Medical Solutions Diagnostics Gmbh | Méthode pour prédire des réponses indésirable à un médicament |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1136554A1 (fr) * | 2000-03-24 | 2001-09-26 | Bayer Aktiengesellschaft | Polymorphismes du gène codant le transporteur à cassette de fixation à l'ATP 1 (ABC1), et usages pour le diagnostique et le traitement de désordres lipidiques, de maladies cardiovasculaires et de maladies inflammatoires |
-
2004
- 2004-01-23 EP EP04704556A patent/EP1592808A2/fr not_active Withdrawn
- 2004-01-23 WO PCT/EP2004/000539 patent/WO2004067774A2/fr active Search and Examination
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1136554A1 (fr) * | 2000-03-24 | 2001-09-26 | Bayer Aktiengesellschaft | Polymorphismes du gène codant le transporteur à cassette de fixation à l'ATP 1 (ABC1), et usages pour le diagnostique et le traitement de désordres lipidiques, de maladies cardiovasculaires et de maladies inflammatoires |
Non-Patent Citations (6)
Title |
---|
DATABASE EMBL [Online] 4 June 1995 (1995-06-04), HABETS ET AL.: "Human T-lymphomia invasion and metastasis inducing TIAM1 protein (TIAM1) mRNA, complete cds." XP002279808 Database accession no. HS162961 cited in the application * |
DORNBROOK-LAVENDER KIMBERLY A ET AL: "Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy." CARDIOVASCULAR DRUGS AND THERAPY, vol. 17, no. 1, January 2003 (2003-01), pages 75-82, XP009030786 ISSN: 0920-3206 (ISSN print) * |
HABETS G G M ET AL: "SEQUENCE OF THE HUMAN INVASION-INDUCING TIAM1 GENE, ITS CONSERVATION IN EVOLUTION AND ITS EXPRESSION IN TUMOR CELL LINES OF DIFFERENT TISSUE ORIGIN" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 10, no. 7, 6 April 1995 (1995-04-06), pages 1371-1376, XP002039499 ISSN: 0950-9232 * |
HWANG DAVID M ET AL: "A genome-based resource for molecular cardiovascular medicine: Toward a compendium of cardiovascular genes" CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 96, no. 12, 16 December 1997 (1997-12-16), pages 4146-4203, XP002197842 ISSN: 0009-7322 cited in the application * |
OHNISHI Y ET AL: "IDENTIFICATION OF 187 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) AMONG 41 CANDIDATE GENES FOR ISCHEMIC HEART DISEASE IN THE JAPANESE POPULATION" HUMAN GENETICS, BERLIN, DE, vol. 106, 2000, pages 288-292, XP002949197 ISSN: 0340-6717 * |
TURNER S T ET AL: "Antihypertensive pharmacogenetics: Getting the right drug into the right patient" JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 19, no. 1, January 2001 (2001-01), pages 1-11, XP002241062 ISSN: 0263-6352 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071382A2 (fr) * | 2005-12-22 | 2007-06-28 | Siemens Medical Solutions Diagnostics Gmbh | Méthode pour prédire des réponses indésirable à un médicament |
WO2007071382A3 (fr) * | 2005-12-22 | 2007-10-11 | Bayer Healthcare Ag | Méthode pour prédire des réponses indésirable à un médicament |
Also Published As
Publication number | Publication date |
---|---|
WO2004067774A3 (fr) | 2004-10-21 |
EP1592808A2 (fr) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6211042B2 (ja) | 心臓血管障害および薬物応答に関連した遺伝子多型、それらの検出方法および用途 | |
US20100190169A1 (en) | Single nucleotide polymorphisms predicting cardiovascular disease | |
US20090138204A1 (en) | Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy | |
EP2310525A1 (fr) | Polymorphismes génétiques associés à des maladies cardiovasculaires et procédés de détection et d'utilisation de ceux-ci | |
US20050123919A1 (en) | Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy | |
WO2006099365A9 (fr) | Polymorphismes genetiques associes a des maladies cardiaques coronariennes, methodes de detection et d'utilisation desdits polymorphismes | |
US20070265217A1 (en) | Single Nucleotide Polymorphisms as Prognostic Tool to Diagnose Adverse Drug Reactions (Adr) and Drug Efficacy | |
US20090208967A1 (en) | Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy | |
US20060240421A1 (en) | Genetic polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy | |
US20090208945A1 (en) | Method for the Prediction of Adverse Drug Responses to Stains | |
EP1592808A2 (fr) | Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament | |
JP2008534019A (ja) | ヒトニーマンピックc1様1遺伝子(npc1l1)多型及びその使用方法 | |
EP1978108A2 (fr) | Polymorphismes nucléotides simples pour prédire les maladies cardiovasculaires et efficacité médicale | |
EP1327639A1 (fr) | Prédiction de maladies cardiovasculaires par polymorphisme génétique de genes associés à ces maladies | |
WO2008052115A1 (fr) | Matériaux et procédés permettant de prédire des réponses physiologiques à des médicaments cardiovasculaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004704556 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004704556 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |